tldrdailynews.com logo
Tag

Apellis

All articles tagged with #apellis

business14 days ago

Biogen closes Apellis deal, pairing two marketed drugs with a nephrology-focused expansion

Biogen completed its all-cash acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and adding the marketed therapies EMPAVELI and SYFOVRE to Biogen’s portfolio, which together generated $689 million in net product revenue in 2025. The deal was financed via a tender offer at $41 per share plus a contingent value right, with about 82% of Apellis shares tendered. Biogen expects the acquisition to be accretive to non-GAAP diluted EPS in 2027 and to enhance long-term growth through nephrology expansion, including felzartamab’s first Phase 3 readout for antibody-mediated rejection in kidney transplant patients in 2027. Updated guidance will be provided with Biogen’s Q2 earnings in July.

via Biogen|
#acquisition#apellis#biogen
business1 month ago

Biogen to Acquire Apellis, Expanding Immunology and Nephrology Footprint

Biogen will acquire Apellis for $41 per share in cash (about $5.6 billion) plus a contingent value right tied to SYFOVRE’s sales, adding two approved medicines—EMPAVELI and SYFOVRE—to Biogen’s growth portfolio and accelerating Biogen’s nephrology plans with Apellis’ team; 2025 combined net product revenue for EMPAVELI and SYFOVRE was $689 million and is expected to grow mid-to-high teens through 2028. Closing is anticipated in Q2 2026, financed by cash and borrowings with plans to de-leverage by 2027. Apellis’ US sales capabilities and nephrology expertise will bolster Biogen’s readiness for felzartamab in Phase 3, while Sobi retains EMPAVELI rights outside the U.S.; the CVR pays up to two $2-per-share amounts based on SYFOVRE sales thresholds and a possible $4-per-share payment in 2031 if higher sales are reached.

via Biogen|
#apellis#biogen#business
Ocugen’s GA gene therapy shows potential edge over rivals in early phase 2 data
healthcare4 months ago

Ocugen’s GA gene therapy shows potential edge over rivals in early phase 2 data

Ocugen reports preliminary phase 2 data for OCU410 to treat geographic atrophy (GA) from dry AMD, with the medium dose showing a 54% reduction in lesion growth vs placebo at 12 months and the high dose 36% in a small patient subset, raising questions about dose response; Ocugen aims to present full data this quarter and move to phase 3 by year-end, targeting an FDA filing in 2028, and argues the therapy could outperform Apellis' Syfovre and Astellas' Izervay.

via Fierce Biotech|
#apellis#geographic-atrophy#healthcare